

Oncología personalizada de precisión: situación actual y perspectivas de futuro

Personalized Precision Oncology: current status and future perspectives

Madrid, 21 de marzo / March 21 2019

BIO

Ignacio Melero Bermejo

Co-director of Department of Immunology and Immunotherapy. Senior investigator and Full Professor of Immunology.

Personal Statement

Dr. Melero started out in biomedical research as a resident of immunology at the prestigious department of this specialty in Hospital Universitario de la Princesa (Madrid). He completed his doctoral thesis with Professor Miguel López-Botet identifying and functionally studying natural killer cell receptors. His work obtained the Outstanding Doctorate Award. In 1994 he joined Bristol Myers Squibb Company as a researcher in cancer immunotherapy in his institute in Seattle (WA). The result of his three years of work in this environment are pioneering publications in the knowledge of costimulation of antitumor immune responses and the use of immunostimulatory monoclonal antibodies. During this period, he worked with Professor Lieping Chen in the division led by Professor Karl E. Hellström. In 1998 he returned to Spain in the field of CIMA and Clínica Universidad de Navarra. In these centers he has led a multidisciplinary team working in cancer immunotherapy with cell therapy techniques, gene therapy and monoclonal antibodies. Dr. Melero is full professor of immunology at the University of Navarra, has directed 12 PhD thesis (6 of them obtained the Outstanding Doctorate Award), and has been principal researcher in over 30 clinical trials of immunotherapy (both sponsored by industry and by the center itself). His work has resulted in three patents transferred to industry. From a bibliometric point of view, Dr. Melero has an h-index of 54 and 223 articles indexed in Medline. For his career he has been awarded the BIAL Medicine award (2004), Conde de Cartagena Award of the Royal Academy of Medicine (2006) and Dr. Durantez award of the LAIR Foundation (2011), among other honors. In 2015 he was appointed director of the Immunology and Immunotherapy department of the Clínica Universidad de Navarra and in 2018 he was appointed Corresponding member of the Royal Nacional Academy of Medicine. The phrase that best defines Dr. Melero's scientific biography is Translational Research in Cancer Immunotherapy in collaboration with pharmaceutical industry and with european groups receiving funding in consortia for the development of therapeutic strategies.

Positions and employment

Medical Resident	Hospital Universitario La Princesa (Madrid)	1989-1993
Research fellow, FIS	Hospital Universitario La Princesa (Madrid)	1994

Postdoctoral Fellow	Bristol Myers Squibb (Seattle, USA)	1994-1995
Investigator	Bristol Myers Squibb (Seattle, USA)	1995-1998
Associate Professor	Facultad de Medicina (Universidad de Navarra)	1998-2004
Senior Research	Universidad de Navarra / FIMA	1998-2005
Full professor of Immunology	Universidad de Navarra	2004-current
Senior Research	Centro de Investigación Médica Aplicada (CIMA)	2005-current
Senior consultant	Oncology (Clínica Universidad de Navarra)	2005-current
Co-Director Immunology and Immunotherapy	Clínica Universidad de Navarra	2015-current

Other Experience and Professional Memberships

Spanish society of Immunology: 1990 member; 1993 full member.

American association of Immunologists: 1996 Regular member.

American society of Gene Therapy. Member. 1998

Asociación española de Terapia génica y celular (2000) Founding member

American Association of Cancer Research (2006).

SENIOR EDITOR: Clinical Cancer Research.

Associate editor in frontiers in immunology

Editorial board Member: Immunotherapy, Autoimmunity, Oncoimmunology, Journal of translational Medicine, World Journal of Immunology and Cancer Immunology Research.

Referee in more than 40 prestigious journals.

Reviewer for: Research projects for ANEP (CICYT y FIS)", "Associazione italiana per la ricerca sul cancro y Referee de Cancer UK (2005, 2006, 2007)". Member of the committee of MEC (2005 y 2016). Evaluator INSERM (France 2008). European Expert (program evaluator Marie Curie y FP7 2006, 2009). Evaluator on clinical trials financing ("call for new therapies from the Ministry of Health 2009 y 2010")

Activity in scientific journals

Ignacio Melero is Senior editor for the Clinical Cancer Research, associate editor in the journal Frontiers in Immunology, executive editor (member of the steering committee) of the journal for immunology of cancer. He is a member of the editorial board of the Journal of Medicine of University of Navarra. Editorial Board Member of Immunotherapy, Autoimmunity, Oncoimmunology, Journal of Translational Medicine, World Journal of Immunology and Cancer Immunology Research.

Dr. Melero has served as a reviewer for the journals: European Journal of Immunology, Journal of Immunology, Human Gene Therapy, Gene Therapy, Cellular Immunology, Cancer Research, Molecular therapy, Nature Reviews Cancer, Nature Medicine, Clinical Cancer Research, International Journal of Cancer, Journal of the National Cancer Institute, Expert Opinion in Biological Therapy, Journal of Hepatology, Current gene therapy, Journal of leukocyte Biology, Blood, Surgical Oncology, PlosOne, PLoS Pathogens, Gastroenterology, Clinical immunology Immunotherapy, Cancer immunology Immunotherapy,

Clinical and Developmental immunology, British Journal of Cancer Immunotherapy, Hematology, International Immunology, trends in immunology, Science Translational Medicine, Future oncology, Frontiers in Immunology, Journal of Translational Medicine, Journal of Immunotherapy, Future Oncology, Oncoimmunology, FASEB Journal, Immunobiology, Molecular Cancer Therapeutics, Nature, Cancer Immunology Research, Journal of Immunotherapy for cancer, New England journal of Medicine.

Ignacio Melero is a regular reviewer of research projects for the ANEP (CICYT and FIS), Member of the Committee of Experts of MEC in the national plan (2005 and 2009), reviewer of the Italian Associazione per la ricerca sul Cancro and Referee Cancer UK (2005 2006, 2007). INSERM Evaluator (France 2008). European expert (evaluator and FP7 Marie Curie 2006, 2009 program). Evaluator of funding clinical trials (call for new therapies of the Health Ministry 2009 and 2010).